SESAME stent trial demonstrates 100% acute success rate in patients undergoing angioplasty of degenerated saphenous vein graft lesions

A new study revealed that the novel self-expanding super-elastic all-metal endoprosthesis stent (SESAME StentTM) used in patients undergoing angioplasty of degenerated saphenous vein graft (SVG) lesions has 100% acute success, low 30 day major adverse cardiac events (MACE) rates, and 9-month patency comparable to balloon expandable stents without embolic protection.

Read the whole article on Science Daily

More from Science Daily